FAMPYRA 10 MG — DIN 02379910
FAMPRIDINE : 10 MG · ACORDA THERAPEUTICS IRELAND LIMITED · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is FAMPYRA?
FAMPYRA 10 MG contains FAMPRIDINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02379910, held by ACORDA THERAPEUTICS IRELAND LIMITED, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Jan-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FAMPYRA used for?
FAMPYRA (fampridine) extended-release tablets are indicated for the symptomatic improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 3.5-7). The initial prescription should be for no more than 4 weeks, and assessment for improvement in walking should be carried out within that timeframe.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Fampridine cost around the world?
Fampridine is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 8 | 8 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 3 | 4 | CZK███.██ |
| Iceland | max wholesale | 3 | 4 | ISK███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| Romania | max producer price | 1 | 2 | RON███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
23 pack listings across 20 brand entries and 8 price bases, refreshed 05 Sep 2026. Ranges span every Fampridine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Fampridine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Fampridine, across 4 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ACORDA THERAPEUTICS IRELAND LIMITED | 1 | 1 | FAMPYRA | Sourceable in Canada |
| PHARMASCIENCE INC | 1 | 1 | PMS-FAMPRIDINE | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 1 | 1 | TARO-FAMPRIDINE | Sourceable in Canada |
| APOTEX INC | 1 | 0 | APO-FAMPRIDINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | Film-coated, white to off-white, biconvex, oval shaped, non-scored tablets with flat edge, debossed with ‘A10' on one side containing 10 mg fampridine. Bottles containing 14 tablets and a silica gel desiccant. Four bottles in a carton. |
| Storage | Store FAMPYRA (fampridine) extended release tablets between 15 to 30° C in the original bottle to protect from light and moisture. Discard medicine after the expiry date shown on the packaging. Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Fampridine |
|---|---|
| ATC code | N07XX07 |
| AHFS class | 92:56.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02379910 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2379910 |
| Brand name | FAMPYRA |
| Generic / active ingredient | FAMPRIDINE : 10 MG |
| Market authorization holder | ACORDA THERAPEUTICS IRELAND LIMITED |
| Health Canada schedule | Prescription |
| ATC code | N07XX07 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N07XX |
| Current status | MARKETED |
| Status date | 08-Jan-2026 |
| Original market date | 2012-02-24 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The maximum recommended dosage of FAMPYRA is one 10 mg tablet twice daily and should not be exceeded. Take doses approximately 12 hours apart. The recommended dose of FAMPYRA (fampridine) extended-release tablets is one 10 mg tablet twice daily. One 10 mg tablet should be taken in the morning and one 10 mg tablet should be taken in the evening. The doses should be taken 12 hours apart. Tablets should only be taken by swallowing whole with a glass of water. Doses should be taken without food. Patients should be advised to not divide, crush, dissolve, suck or chew the tablet because broken tablets can release too much of the drug at one time and increase the risk of seizure adverse events. Patients should also be advised not to take an extra dose if a dose is missed, due to the increased risk of seizure adverse events. The initial prescription for FAMPYRA should be for no more than 4 weeks of therapy as clinical benefits should generally be identified within 4 weeks after starting FAMPYRA. The assessment for evaluation of improvement should be conducted prior to starting treatment and again within 4 weeks. FAMPYRA should be discontinued if benefit is not reported by patient. Physicians should continue to actively review the benefit/risk of FAMPYRA for the individual patient, to ensure continued positive benefit/risk. In all cases, FAMPYRA should be discontinued if patients no longer report benefit, or if seizure occurs.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
FAMPYRA (fampridine) extended-release tablets are contraindicated in: Patients who are hypersensitive to FAMPYRA or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed in patients treated with fampridine. Patients taking concurrent compounded 4-aminopyridine or other forms of fampridine. Patients with moderate or severe renal impairment (creatinine clearance <50mL/min). Patients with a prior history or current presentation of seizure. Patients taking medicinal products that are inhibitors of the renal Organic Cation Transporter 2 (OCT2), such as cimetidine and quinidine.
Warnings and precautions
FAMPYRA should be used under the supervision of a clinician experienced in the treatment of multiple sclerosis. Recommended dose should not be exceeded due to an increased risk of seizure. Treatment with fampridine increases seizure risk, with a dose-dependent increase observed in clinical studies at doses above 10 mg twice daily. Renal impairment and certain concomitant medications can increase fampridine plasma levels, increasing seizure risk. Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed, sometimes after the first dose. Patients should be informed of serious allergic reaction symptoms and seek immediate emergency assistance if they occur. Concurrent treatment with other forms of 4-aminopyridine is contraindicated. FAMPYRA is a potassium channel blocker and should be administered with caution to patients with cardiovascular symptoms of rhythm and sinoatrial or atrioventricular conduction cardiac disorders. Dizziness or fatigue may occur, caution is advised for activities requiring mental alertness. A higher incidence of urinary tract infections (UTI) was reported with FAMPYRA (12%) than with placebo (8%). Exacerbation of Trigeminal Neuralgia has been reported in MS patients with a history of TN during postmarketing experience.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PMS-FAMPRIDINE | 10 MG | TABLET (EXTENDED-RELEASE) | PHARMASCIENCE INC | MARKETED | 02496216 |
| TARO-FAMPRIDINE | 10 MG | TABLET (EXTENDED-RELEASE) | TARO PHARMACEUTICALS INC | MARKETED | 02482398 |
| APO-FAMPRIDINE | 10 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | APPROVED | 02491672 |
2 · Same class — other molecules in ATC N07XX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fampridine | APO-FAMPRIDINE · FAMPYRA · PMS-FAMPRIDINE · TARO-FAMPRIDINE | 4 | 3 | Yes |
| Tetrabenazine | APO-TETRABENAZINE · NITOMAN · PMS-TETRABENAZINE · TETRABENAZINE TABLETS | 4 | 3 | Yes |
| Riluzole | APO-RILUZOLE · MYLAN-RILUZOLE · RILUTEK | 3 | 3 | Yes |
| Amifampridine | FIRDAPSE · RUZURGI | 2 | 2 | Yes |
| Hydroxybutyric Acid | XYREM · XYWAV | 2 | 2 | Yes |
| Pitolisant | WAKIX | 2 | 2 | Yes |
| Tafamidis | VYNDAMAX · VYNDAQEL | 2 | 2 | Yes |
| Edaravone | RADICAVA | 2 | 1 | Yes |
| Trofinetide | DAYBUE | 1 | 1 | Yes |
| Eplontersen | WAINUA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is FAMPYRA called?
Also recorded in Canada as: 12 HR dalfampridine 10 MG Extended Release Oral Tablet [Ampyra] (US), 12 HR dalfampridine 10 MG Extended Release Oral Tablet (US), AMIFAMPRIDINE PHOSPHATE (US), DALFAMPRIDINE (US), AMPYRA (US), DALYMPA (IN), FAMPRIDINE (GLOBAL), 4-AMINOPYRIDINE (GLOBAL), 4-AP (GLOBAL), FAMPRIDINE SR (GLOBAL).
The same molecule, Fampridine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Fampyra (Lyfjaver) | Latin | Iceland |
| FAMPRIDIN SANDOZ | Latin | Czechia |
| FAMPRIDINE TEVA | Latin | Czechia |
| Fampyra (Heilsa) | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.